Intervention

ofatumumab

ClinicalTrials.gov intervention label

Clinical trials14

Recruiting1

Common conditions8

Lead sponsors shown5

Clinical trials

14 shown

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisNCT05344469 · 2022-05-10

Switch to Ofatumumab and Level of ImmunoglobulinsNCT07625800 · 2026-06-01

NOT_YET_RECRUITING

An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).NCT07546110 · 2026-05-01

NOT_YET_RECRUITING

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple SclerosisNCT06551519 · 2024-10-23

ACTIVE_NOT_RECRUITING

A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical PracticeNCT06251986 · 2024-02-26

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in FranceNCT06157086 · 2023-12-21

ACTIVE_NOT_RECRUITING

WOE of Anti-CD20 TherapiesNCT06121349 · 2023-12-04

The 'Wearing Off' Effect of DMTNCT05627271 · 2023-01-10

Characterizing the Use of Ofatumumab in a Real World SettingNCT05090033 · 2022-12-08

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT01578707 · 2012-06-01

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic LeukemiaNCT00742144 · 2008-09-19

Study to Evaluate SC Route of Administration of Ofatumumab in RA PatientsNCT00686868 · 2008-06-13

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403NCT00655824 · 2008-01-01

Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX TherapyNCT00611455 · 2008-01-01

Common conditions

Multiple Sclerosis5 Arthritis, Rheumatoid3 Relapsing Multiple Sclerosis2 Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular1 Multiple Sclerosis (MS)1 Relapsed or Refractory Chronic Lymphocytic Leukemia1 Relapsing Forms of Multiple Sclerosis1 Small Lymphocytic Lymphoma1

Leading sponsors

Novartis Pharmaceuticals7 GlaxoSmithKline4 Pharmacyclics LLC.1 The Affiliated Hospital of Xuzhou Medical University1 University Hospital, Lille1

Trial status mix

COMPLETED7

ACTIVE_NOT_RECRUITING2

NOT_YET_RECRUITING2

TERMINATED2

RECRUITING1

Phase mix

PHASE12

PHASE32

EARLY_PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.